![Will 20mg for 6 months be enough? My derm said they don't go by cumulative dose, as there are studies that it doesn't matter? (More info in the comments) : r/Accutane Will 20mg for 6 months be enough? My derm said they don't go by cumulative dose, as there are studies that it doesn't matter? (More info in the comments) : r/Accutane](https://preview.redd.it/will-20mg-for-6-months-be-enough-my-derm-said-they-dont-go-v0-ecadpyyie3h81.jpg?width=640&crop=smart&auto=webp&s=c4e3e591c862e3184c48786fb68803cd40d1646c)
Will 20mg for 6 months be enough? My derm said they don't go by cumulative dose, as there are studies that it doesn't matter? (More info in the comments) : r/Accutane
![New Formulations of Isotretinoin for Acne Treatment: Expanded Options and Clinical Implications – JCAD | The Journal of Clinical and Aesthetic Dermatology New Formulations of Isotretinoin for Acne Treatment: Expanded Options and Clinical Implications – JCAD | The Journal of Clinical and Aesthetic Dermatology](https://jcadonline.com/wp-content/uploads/BellomoDec2021_Table1.gif)
New Formulations of Isotretinoin for Acne Treatment: Expanded Options and Clinical Implications – JCAD | The Journal of Clinical and Aesthetic Dermatology
![The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3970835/bin/jcad_7_2_suppl-g002.jpg)
The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC
![Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. | Semantic Scholar Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b1ae13cbff808f611e6893de6e4ef91c5495bce0/3-Figure1-1.png)
Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. | Semantic Scholar
View of Comparative Pharmacokinetic Profiles of a Novel Low-dose Micronized-isotretinoin 32 mg Formulation and Lidose-isotretinoin 40 mg in Fed and Fasted Conditions: Two Open-label, Randomized, Crossover Studies in Healthy Adult Participants
![Prescribing isotretinoin for patients with acne in primary care - Best Practice Advocacy Centre New Zealand Prescribing isotretinoin for patients with acne in primary care - Best Practice Advocacy Centre New Zealand](https://bpac.org.nz/2017/img/isochart.jpg)
Prescribing isotretinoin for patients with acne in primary care - Best Practice Advocacy Centre New Zealand
![Oral isotretinoin in different dose regimens for acne vulgaris: A randomized comparative trial - Indian Journal of Dermatology, Venereology and Leprology Oral isotretinoin in different dose regimens for acne vulgaris: A randomized comparative trial - Indian Journal of Dermatology, Venereology and Leprology](https://ijdvl.com/content/126/2011/77/6/Images/ijdvl_2011_77_6_688_86482_t5.jpg)
Oral isotretinoin in different dose regimens for acne vulgaris: A randomized comparative trial - Indian Journal of Dermatology, Venereology and Leprology
![The face I give my derm after being on accutane for 9 months, hitting my cumulative dose, & having pretty damn clear skin for the last 4 months, when he tells me “ The face I give my derm after being on accutane for 9 months, hitting my cumulative dose, & having pretty damn clear skin for the last 4 months, when he tells me “](https://i.redd.it/1b2ink3cbcn71.jpg)
The face I give my derm after being on accutane for 9 months, hitting my cumulative dose, & having pretty damn clear skin for the last 4 months, when he tells me “
![The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3970835/bin/jcad_7_2_suppl-g005.jpg)
The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC
![The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3970835/bin/jcad_7_2_suppl-g004.jpg)
The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. - Abstract - Europe PMC
![Prescribing isotretinoin for patients with acne in primary care - Best Practice Advocacy Centre New Zealand Prescribing isotretinoin for patients with acne in primary care - Best Practice Advocacy Centre New Zealand](https://bpac.org.nz/2017/img/isochart2.jpg)
Prescribing isotretinoin for patients with acne in primary care - Best Practice Advocacy Centre New Zealand
![An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period – JCAD | The Journal of An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period – JCAD | The Journal of](https://jcadonline.com/wp-content/uploads/DelRossoNov2019Table2.gif)
An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period – JCAD | The Journal of
![Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. | Semantic Scholar Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b1ae13cbff808f611e6893de6e4ef91c5495bce0/3-Table3-1.png)